Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Dofetilide Articles

Pfizer and Warner-Lambert merger creates industry's largest R&D budget

10 February 2000

Pfizer reveals new products in bid to boost profile after hostile bid for

18 November 1999

FDA backs Pfizer's dofetilide, launch slated for early 2000

11 October 1999

Stock Commentary New York

11 October 1999

FDA recommends approval of Pfizer's Tikosyn

3 February 1999

Pfizer named company of the year by Forbes

31 December 1998

Pfizer Aims For Top Slot After Millenium

10 November 1998

Minor Setback With Droloxifene For Pfizer

29 January 1998

DIAMOND-MI Supports Dofetilide Benefit

20 November 1997

New Studies At European Cardiology Meeting

15 September 1997

Pfizer Enters New Product Cycle With Strong Potential

7 August 1997

Pfizer Presents Fertile Pipeline

6 November 1995

Pfizer's Fruitful Product Pipeline

7 November 1994

Pfizer: Record Number Of Drugs In Phases II & III

31 October 1994

PFIZER "CONFIDENT" IN CHANGING ENVIRONMENT

3 May 1993

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS